

*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.

1. (Previously Presented) Tetrapeptide Lys-Glu-Asp-Trp-NH<sub>2</sub>[SEQ ID NO:1].
2. (Canceled).
3. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically admissible carrier and tetrapeptide Lys-Glu-Asp-Trp-NH<sub>2</sub>[SEQ ID NO:1].
4. (Currently Amended) The pharmaceutical composition of claim 3, which is ~~suitable for oral administration~~ an oral formulation.
5. (Currently Amended) The pharmaceutical composition of claim 3, which is ~~suitable for parenteral administration~~ a parenteral formulation.
6. (Previously Presented) A method of treatment of diabetes mellitus, which consists in administering to the patient an effective amount of tetrapeptide Lys-Glu-Asp-Trp-NH<sub>2</sub> [SEQ ID NO:1] at least once a day for a period necessary for attaining a therapeutic effect.
7. (Previously Presented) The method of claim 6 wherein the tetrapeptide is administered parenterally.
8. (Previously Presented) The method of claim 6 wherein the tetrapeptide is administered orally.
9. (Previously Presented) The method of claim 6 wherein the tetrapeptide is administered in doses of 0.1-30 mg/kg of the body weight.